Anti-Mouse CD3ε (Clone 145-2C11) F(ab’)2 fragment – Purified in vivo GOLD™ Functional Grade

H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Depletion

Clone 145-2C11 recognizes an epitope on mouse CD3ε.

Derived from the 145-2C11 monoclonal antibody, this product provides the F(ab’)2 fragment, targeting the 20 kDa transmembrane CD3ε protein, a crucial component of the TCR complex on T lymphocytes, NK-T cells, and thymocytes. Pepsin digestion removes the Fc region, ensuring minimal non-specific binding and preventing Fcγ receptor-mediated cross-linking. This F(ab’)2 fragment is designed for in vivo applications where the full 145-2C11 antibody's T cell activation can lead to adverse effects. It induces apoptosis in antigen-activated T cells by promoting sustained TCR expression and signaling, while Foxp3+ regulatory T cells remain unaffected.

CD3ε is primarily expressed on mature T cells and NK-T cells and at different levels on differentiation-dependent thymocytes.

Peptide antigen/MHC-complex

TCR signal transduction, T cell activation, antigen recognition

1.) Abdulreda, M.H. et al. (2019) Diabetologia. 63, 237–1250
2.) Skyberg, J. A. et al. (2020) Infection and Immunity. 88: 5. Journal Link